A Phase 3 interventional study of Vortioxetine (Lu AA21004) in Major Depressive Disorder, sponsored by H. Lundbeck A/S. Completed. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2014-04-01.
Sponsored by H. Lundbeck A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies testing vortioxetine in Depressive Disorder, Major — 1 open to participants now, 1 under way, 1 of them phase 3. Vortioxetine · Depressive Disorder, Major.
Among the 54 studies testing vortioxetine in Depressive Disorder, Major, this one is the 18th largest by enrollment, is one of 6 that started in 2008, is one of 31 in phase 3, and was the 5th registered.
3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.
Browse Depressive Disorder, Major studies →1 of the 54 studies testing vortioxetine in Depressive Disorder, Major is open now, in 1 country. Recruiting first, the newest first:
Takeda · Sites in Japan
Ages 12–17
By country, each count listing its studies:
Vortioxetine: first FDA approval 2013 (TRINTELLIX), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 8 · Phase 3 33 · Phase 4 13
First in 2006; this study’s year is marked. 6 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 535 is above the median of 80 across 2,534 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 413 across the 54 interventional studies. Of the 46 that completed or were terminated, 32 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
44 of 54 have an industry lead sponsor. The 10 most frequent:
H. Lundbeck A/S is the lead sponsor of 224 studies on the registry; 9 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 10 (30%) have results posted.
36 studies in Depressive Disorder, Major by H. Lundbeck A/S: none open now, none under way, none of them phase 3. Of 36 finished, 20 (56%) have results posted.
Among the 36 studies in Depressive Disorder, Major by H. Lundbeck A/S, this one is the 11th largest by enrollment of the 34 interventional ones that give a count, is one of 4 that started in 2008, is one of 21 in phase 3, and was the 4th registered.
H. Lundbeck A/S’s Depressive Disorder, Major studies by the year they started, since 2005.
None of the studies under way reaches primary completion within a year.
Among the 54 studies testing vortioxetine in Depressive Disorder, Major, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among H. Lundbeck A/S’s 36 in Depressive Disorder, Major:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to evaluate long-term safety and tolerability of Vortioxetine over a period of 52 weeks in patients with Major Depressive Disorder (MDD) having completed 8-week acute treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion and exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Vortioxetine (Lu AA21004)
2.5, 5, or 10 mg/day; tablets; orally
Also known as: Brintellix
Number of Patients With Adverse Events (AEs)
Time frame: Baseline to end of the 4-week safety follow-up period
Percentage of Patients Who Withdrew Due to Intolerance to Treatment
Time frame: Baseline to Week 52
Change From Baseline in MADRS Total Score After 52 Weeks of Treatment
The Montgomery Åsberg Depression Rating Scale (MADRS) is a depression rating scale consisting of 10 items, each rated 0 (no symptom) to 6 (severe symptom). The 10 items represent the core symptoms of depressive illness. The rating should be based on a clinical interview with the patient, moving from broadly phrased questions about symptoms to more detailed ones, which allow a precise rating of severity, covering the last 7 days. Total score from 0 to 60. The higher the score, the more severe.
Time frame: Baseline and Week 52
Change From Baseline in HAM-D-24 Total Score After 52 Weeks of Treatment
The Hamilton Depression Scale - 24 Items (HAM-D-24) measures depression severity. Items are rated on a scale from 0 (symptoms not present) to a maximum of 2 to 4 (symptom extremely severe) for a total score range of 0 to 76. The higher the score, the more severe.
Time frame: Baseline and Week 52
Change From Baseline in HAM-A Total Score After 52 Weeks of Treatment
The Hamilton Anxiety Rating Scale (HAM-A) consists of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behaviour at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic, and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total score from 0 to 56. The higher the score, the more severe.
Time frame: Baseline and Week 52
Change From Baseline in CGI-S Score After 52 Weeks of Treatment
The Clinical Global Impression - Severity of Illness (CGI-S) is a 7-point scale rated from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). The investigator should use his/her total clinical experience with this patient population to judge how mentally ill the patient is at the time of rating.
Time frame: Baseline and Week 52
Proportion of Responders at Week 52 (Response Defined as a >=50% Decrease in MADRS Total Score)
Time frame: Week 52
Proportion of Remitters at Week 52 (Remission Defined as a MADRS Total Score <=10)
Time frame: Week 52
Proportion of Patients With a MADRS Total Score >=22 After 52 Weeks of Treatment
Time frame: Baseline and Week 52
Change From Baseline in SDS Total Score After 52 Weeks of Treatment
The Sheehan Disability Scale (SDS) comprises self-rated items designed to measure impairment. The patient rates the extent to which his or her (1) work, (2) social life or leisure activities and (3) home life or family responsibilities are impaired on a 10-point visual analogue scales, on which 0 = normal functioning and 10 = severe functional impairment. The three items may be summed into a single dimensional measure of global functional impairment that ranges from 0 (unimpaired) to 30 (highly impaired). The higher the score, the more severe.
Time frame: Baseline and Week 52
Patients eligible to participate in Study 11984B were patients who had completed lead-in Study NCT00635219 / 11984A immediately prior to inclusion into Study 11984B.
| Milestone | Vortioxetine 2.5, 5, or 10 mg/Day |
|---|---|
| Started | 535 |
| Completed | 328 |
| Not completed | 207 |
| Withdrew: Adverse event | 42 |
| Withdrew: Lack of efficacy | 35 |
| Withdrew: Non-compliance with study product | 16 |
| Withdrew: Protocol violation | 6 |
| Withdrew: Withdrawal of consent | 61 |
| Withdrew: Lost to follow-up | 15 |
| Withdrew: Administrative or other reasons | 32 |
| participants | Vortioxetine 2.5, 5, or 10 mg/Day |
|---|---|
| Patients With AEs | 391 |
| Patients With SAEs | 18 |
| Patients With AEs Leading to Withdrawal | 42 |
| percentage of patients | Vortioxetine 2.5, 5, or 10 mg/Day |
|---|---|
| Percentage of Patients Who Withdrew Due to Intolerance to Treatment | 7.7 |
The Montgomery Åsberg Depression Rating Scale (MADRS) is a depression rating scale consisting of 10 items, each rated 0 (no symptom) to 6 (severe symptom). The 10 items represent the core symptoms of depressive illness. The rating should be based on a clinical interview with the patient, moving from broadly phrased questions about symptoms to more detailed ones, which allow a precise rating of severity, covering the last 7 days. Total score from 0 to 60. The higher the score, the more severe.
| units on a scale | Vortioxetine 2.5, 5, or 10 mg/Day |
|---|---|
| Change From Baseline in MADRS Total Score After 52 Weeks of Treatment | -7.35 ± 8.21 |
The Hamilton Depression Scale - 24 Items (HAM-D-24) measures depression severity. Items are rated on a scale from 0 (symptoms not present) to a maximum of 2 to 4 (symptom extremely severe) for a total score range of 0 to 76. The higher the score, the more severe.
| units on a scale | Vortioxetine 2.5, 5, or 10 mg/Day |
|---|---|
| Change From Baseline in HAM-D-24 Total Score After 52 Weeks of Treatment | -6.86 ± 8.45 |
The Hamilton Anxiety Rating Scale (HAM-A) consists of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behaviour at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic, and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total score from 0 to 56. The higher the score, the more severe.
| units on a scale | Vortioxetine 2.5, 5, or 10 mg/Day |
|---|---|
| Change From Baseline in HAM-A Total Score After 52 Weeks of Treatment | -5.44 ± 7.08 |
The Clinical Global Impression - Severity of Illness (CGI-S) is a 7-point scale rated from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). The investigator should use his/her total clinical experience with this patient population to judge how mentally ill the patient is at the time of rating.
| units on a scale | Vortioxetine 2.5, 5, or 10 mg/Day |
|---|---|
| Change From Baseline in CGI-S Score After 52 Weeks of Treatment | -1.00 ± 1.22 |
| percentage of patients | Vortioxetine 2.5, 5, or 10 mg/Day |
|---|---|
| Proportion of Responders at Week 52 (Response Defined as a >=50% Decrease in MADRS Total Score) | 94.2 ± 23.4 |
| percentage of patients | Vortioxetine 2.5, 5, or 10 mg/Day |
|---|---|
| Proportion of Remitters at Week 52 (Remission Defined as a MADRS Total Score <=10) | 83.0 ± 37.6 |
| percentage of patients | Vortioxetine 2.5, 5, or 10 mg/Day |
|---|---|
| Proportion of Patients With a MADRS Total Score >=22 After 52 Weeks of Treatment | 2.74 |
The Sheehan Disability Scale (SDS) comprises self-rated items designed to measure impairment. The patient rates the extent to which his or her (1) work, (2) social life or leisure activities and (3) home life or family responsibilities are impaired on a 10-point visual analogue scales, on which 0 = normal functioning and 10 = severe functional impairment. The three items may be summed into a single dimensional measure of global functional impairment that ranges from 0 (unimpaired) to 30 (highly impaired). The higher the score, the more severe.
| units on a scale | Vortioxetine 2.5, 5, or 10 mg/Day |
|---|---|
| Change From Baseline in SDS Total Score After 52 Weeks of Treatment | -5.60 ± 6.91 |
Collected over Serious Adverse Events: 52-week open label period and 4-week safety follow-up period Other Adverse Events: 52-week open label period. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Vortioxetine 2.5, 5, or 10 mg/Day | — | 18/535 (3.4%) | 256/535 (47.9%) |
| Event | Vortioxetine 2.5, 5, or 10 mg/Day |
|---|---|
| DepressionPsychiatric disorders | 3/535 |
| Suicidal ideationPsychiatric disorders | 3/535 |
| MenorrhagiaReproductive system and breast disorders | 1/366 |
| Chest painGeneral disorders | 1/535 |
| AppendicitisInfections and infestations | 1/535 |
| PneumoniaInfections and infestations | 1/535 |
| Intentional overdoseInjury, poisoning and procedural complications | 1/535 |
| Road traffic accidentInjury, poisoning and procedural complications | 1/535 |
| Back painMusculoskeletal and connective tissue disorders | 1/535 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 1/535 |
| Event | Vortioxetine 2.5, 5, or 10 mg/Day |
|---|---|
| NauseaGastrointestinal disorders | 106/535 |
| HeadacheNervous system disorders | 82/535 |
| NasopharyngitisInfections and infestations | 56/535 |
| InsomniaPsychiatric disorders | 38/535 |
| DizzinessNervous system disorders | 34/535 |
| Weight increasedInvestigations | 31/535 |
| Accidental overdoseInjury, poisoning and procedural complications | 29/535 |
| InfluenzaInfections and infestations | 27/535 |
Age and Sex: all-patients-treated set (APTS) - all patients who took at least one dose of Vortioxetine after Baseline; MADRS, HAM-D-24, HAM-A, CGI-S and SDS: full-analysis set (FAS) - all patients in the APTS who had at least one valid post-Baseline assessment of the MADRS total score.
| Age, Continuous(years) | Vortioxetine 2.5, 5, or 10 mg/Day |
|---|---|
| Mean | 45.7 ± 12.3 |
| Sex: Female, Male(Participants) | Vortioxetine 2.5, 5, or 10 mg/Day |
|---|---|
| Female | 366 |
| Male | 169 |
| MADRS(units on a scale) | Vortioxetine 2.5, 5, or 10 mg/Day |
|---|---|
| Mean | 13.5 ± 8.7 |
| HAM-D-24(units on a scale) | Vortioxetine 2.5, 5, or 10 mg/Day |
|---|---|
| Mean | 13.4 ± 8.7 |
| HAM-A(units on a scale) | Vortioxetine 2.5, 5, or 10 mg/Day |
|---|---|
| Mean | 11.0 ± 7.2 |
| CGI-S(units on a scale) | Vortioxetine 2.5, 5, or 10 mg/Day |
|---|---|
| Mean | 2.7 ± 1.2 |
| SDS(units on a scale) | Vortioxetine 2.5, 5, or 10 mg/Day |
|---|---|
| Mean | 12.42 ± 8.13 |
No study locations are listed for this record.
The record gives a start of May 2008, a primary completion of Mar 2010 and a completion of Apr 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2014, 4 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vortioxetine